Influence of PEI as a core modifying agent on PLGA microspheres of PGE 1, a pulmonary selective vasodilator

International Journal of Pharmaceutics

Volumn 413, Issue 1-2, 2011, Pages 51-62

  Gupta, Vivek ^a,b   Ahsan, Fakhrul ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Santa Barbara   (United States)

Author keywords

Core modifying polyethyleneimine; PLGA microparticles; Prostaglandin E 1; Pulmonary arterial hypertension; Pulmonary delivery

Indexed keywords

MICROSPHERE; POLYETHYLENEIMINE; POLYGLACTIN; POLYVINYL ALCOHOL; PROSTAGLANDIN E1; SOLVENT;

ACUTE TOXICITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG RELEASE; EMULSION; EPITHELIUM CELL; EVAPORATION; HALF LIFE TIME; IN VITRO STUDY; IN VIVO STUDY; INHALATION; LUNG FLUID; LUNG HOMOGENATE; LUNG LAVAGE; MALE; MATERIAL COATING; NONHUMAN; OSMOTIC PRESSURE; PARTICLE SIZE; PRESSURE GRADIENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; RESPIRATORY EPITHELIUM; SURFACE PROPERTY;

ADMINISTRATION, INHALATION; ALPROSTADIL; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CELL SURVIVAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; EXCIPIENTS; EXTRACELLULAR FLUID; LACTIC ACID; LUNG; MALE; MICROSPHERES; PARTICLE SIZE; POLYETHYLENEIMINE; POLYGLYCOLIC ACID; POLYVINYL ALCOHOL; RATS; RATS, SPRAGUE-DAWLEY; SURFACE PROPERTIES; VASODILATOR AGENTS;

EID: 79958002525     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.04.017     Document Type: Article

References (47)

1. A. Adjei, and J. Garren Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers Pharm. Res. 7 1990 565 569 (Pubitemid 20286520)
2. B.D. Beck, J.D. Brain, and D.E. Bohannon An in vivo hamster bioassay to assess the toxicity of particulates for the lungs Toxicol. Appl. Pharmacol. 66 1982 9 29 (Pubitemid 13202176)
3. Y. Cirpanli, N. Unlu, S. Calis, and A.A. Hincal Formulation and in-vitro characterization of retinoic acid loaded poly (lactic-co-glycolic acid) microspheres J. Microencapsul. 22 2005 877 889 (Pubitemid 43158189)
4. R.O. Cook, R.K. Pannu, and I.W. Kellaway Novel sustained release microspheres for pulmonary drug delivery J. Control. Release 104 2005 79 90 (Pubitemid 40615237)
5. C.B. Daniels, and S. Orgeig Pulmonary surfactant: the key to the evolution of air breathing News Physiol. Sci. 18 2003 151 157 (Pubitemid 37026104)
6. N.M. Davies, and M.R. Feddah A novel method for assessing dissolution of aerosol inhaler products Int. J. Pharm. 255 2003 175 187 (Pubitemid 36369601)
7. D.A. Edwards, J. Hanes, G. Caponetti, J. Hrkach, A. Ben-Jebria, M.L. Eskew, J. Mintzes, D. Deaver, N. Lotan, and R. Langer Large porous particles for pulmonary drug delivery Science 276 1997 1868 1871 (Pubitemid 27443665)
8. R. Ewert, C.F. Opitz, R. Wensel, J. Winkler, M. Halank, and S.B. Felix Continuous intravenous iloprost to revert treatment failure of first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension Clin. Res. Cardiol. 96 2007 211 217 (Pubitemid 46482302)
9. K.A. Foster, M.L. Avery, M. Yazdanian, and K.L. Audus Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery Int. J. Pharm. 208 2000 1 11
10. S.K. Gill, A.M. Shobe, and L.J. Hope-Weeks Synthesis of cobalt oxide aerogels and nanocomposite systems containing single-walled carbon nanotubes Scanning 31 2009 132 138
11. A.B. Goldsobel, and B.E. Chipps Cough in the pediatric population J. Pediatr. 156 2010 352 358
12. M. Gomberg-Maitland, and H. Olschewski Prostacyclin therapies for the treatment of pulmonary arterial hypertension Eur. Respir. J. 31 2008 891 901
13. V. Gupta, and F. Ahsan Inhalational therapy for pulmonary arterial hypertension: current status and future prospects Crit. Rev. Ther. Drug Carrier Syst. 27 2010 313 370
14. 1-HPβCD) complex for the treatment of pulmonary arterial hypertension (PAH). Pharm. Res. DOI:10.1007/s11095-011-0409-6.
15. V. Gupta, A. Rawat, and F. Ahsan Feasibility study of aerosolized prostaglandin E1 microspheres as a noninvasive therapy for pulmonary arterial hypertension J. Pharm. Sci. 99 2010 1774 1789
16. R.F. Henderson, E.G. Damon, and T.R. Henderson Early damage indicators in the the lung. I. Lactate dehydrogenase activity in the airways Toxicol. Appl. Pharmacol. 44 1978 291 297 (Pubitemid 8365677)
17. K. Hirota, T. Hasegawa, T. Nakajima, H. Inagawa, C. Kohchi, G. Soma, K. Makino, and H. Terada Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis J. Control. Release 142 2010 339 346
18. A. Hussain, and F. Ahsan State of insulin self-association does not affect its absorption from the pulmonary route Eur. J. Pharm. Sci. 25 2005 289 298 (Pubitemid 40725059)
19. Y.I. Jeong, J.G. Song, S.S. Kang, H.H. Ryu, Y.H. Lee, C. Choi, B.A. Shin, K.K. Kim, K.Y. Ahn, and S. Jung Preparation of poly(dl-lactide-co-glycolide) microspheres encapsulating all-trans retinoic acid Int. J. Pharm. 259 2003 79 91 (Pubitemid 36638556)
20. R. Jeyanthi, R.C. Mehta, B.C. Thanoo, and P.P. DeLuca Effect of processing parameters on the properties of peptide-containing PLGA microspheres J. Microencapsul. 14 1997 163 174 (Pubitemid 27095967)
21. N.R. Labiris, and M.B. Dolovich Pulmonary drug delivery. Part I. Physiological factors affecting therapeutic effectiveness of aerosolized medications Br. J. Clin. Pharmacol. 56 2003 588 599 (Pubitemid 37491710)
22. S.C. Lee, J.T. Oh, M.H. Jang, and S.I. Chung Quantitative analysis of polyvinyl alcohol on the surface of poly(d,l-lactide-co-glycolide) microparticles prepared by solvent evaporation method: effect of particle size and PVA concentration J. Control. Release 59 1999 123 132 (Pubitemid 29199919)
23. S.H. Lee, and L.J. Rubin Current treatment strategies for pulmonary arterial hypertension J. Intern. Med. 258 2005 199 215 (Pubitemid 41243051)
24. D. Lemoine, and V. Preat Polymeric nanoparticles as delivery system for influenza virus glycoproteins J. Control. Release 54 1998 15 27 (Pubitemid 28255234)
25. B.J. Lipworth New perspectives on inhaled drug delivery and systemic bioactivity Thorax 50 1995 105 110
26. J. Meyer, G. Theilmeier, H. Van Aken, H.G. Bone, H. Busse, R. Waurick, F. Hinder, and M. Booke Inhaled prostaglandin E1 for treatment of acute lung injury in severe multiple organ failure Anesth. Analg. 86 1998 753 758 (Pubitemid 28177727)
27. O.R. Moss Simulants of lung interstitial fluid Health Phys. 36 1979 447 448 (Pubitemid 9218628)
28. J. Nakano, A.V. Prancan, and N.H. Morsy Metabolism of prostaglandin E1 in stomach, jejunum chyle and plasma of the dog and the rat Jpn. J. Pharmacol. 23 1973 355 361
29. A.L. Nieminen, G.J. Gores, J.M. Bond, R. Imberti, B. Herman, and J.J. Lemasters A novel cytotoxicity screening assay using a multiwell fluorescence scanner Toxicol. Appl. Pharmacol. 115 1992 147 155
30. K. Ohashi, T. Kabasawa, T. Ozeki, and H. Okada One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis J. Control. Release 135 2009 19 24
31. H. Olschewski, G. Simonneau, N. Galie, T. Higenbottam, R. Naeije, L.J. Rubin, S. Nikkho, R. Speich, M.M. Hoeper, J. Behr, J. Winkler, O. Sitbon, W. Popov, H.A. Ghofrani, A. Manes, D.G. Kiely, R. Ewert, A. Meyer, P.A. Corris, M. Delcroix, M. Gomez-Sanchez, H. Siedentop, and W. Seeger Inhaled iloprost for severe pulmonary hypertension N. Engl. J. Med. 347 2002 322 329 (Pubitemid 34815354)
32. A. Papi, G.W. Canonica, P. Maestrelli, P. Paggiaro, D. Olivieri, E. Pozzi, N. Crimi, A.M. Vignola, P. Morelli, G. Nicolini, and L.M. Fabbri Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma N. Engl. J. Med. 356 2007 2040 2052 (Pubitemid 46789894)
33. J.W. Park, O.C. Jeon, S.K. Kim, T.A. Al-Hilal, H.T. Moon, C.Y. Kim, and Y. Byun Anticoagulant efficacy of solid oral formulations containing a new heparin derivative Mol. Pharm. 7 2010 836 843
34. P.I.P. Park, and S. Jonnalagadda Predictors of glass transition in the biodegradable polylactide and poly-lactide-co-glycolide polymers J. Appl. Polym. Sci. 100 2006 1983 1987
35. E.J. Pavlik, R.C. Flanigan, J.R. van Nagell Jr., M.B. Hanson, E.S. Donaldson, K. Keaton, B. Doss, J. Bartmas, and D.E. Kenady Esterase activity, exclusion of propidium iodide, and proliferation in tumor cells exposed to anticancer agents: phenomena relevant to chemosensitivity determinations Cancer Invest. 3 1985 413 426 (Pubitemid 16257591)
36. K.F. Pistel, and T. Kissel Effects of salt addition on the microencapsulation of proteins using W/O/W double emulsion technique J. Microencapsul. 17 2000 467 483 (Pubitemid 30420829)
37. T. Qian, A.L. Nieminen, B. Herman, and J.J. Lemasters Mitochondrial permeability transition in pH-dependent reperfusion injury to rat hepatocytes Am. J. Physiol. 273 1997 C1783 C1792
38. H.B. Ravivarapu, H. Lee, and P.P. DeLuca Enhancing initial release of peptide from poly(d,l-lactide-co-glycolide) (PLGA) microspheres by addition of a porosigen and increasing drug load Pharm. Dev. Technol. 5 2000 287 296 (Pubitemid 30247109)
39. A. Rawat, Q.H. Majumder, and F. Ahsan Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation J. Control. Release 128 2008 224 232
40. C.P. Ricachinevsky, and S.L. Amantea Treatment of pulmonary arterial hypertension J. Pediatr. (Rio J) 82 2006 S153 S165
41. L.J. Rubin, D.B. Badesch, R.J. Barst, N. Galie, C.M. Black, A. Keogh, T. Pulido, A. Frost, S. Roux, I. Leconte, M. Landzberg, and G. Simonneau Bosentan therapy for pulmonary arterial hypertension N. Engl. J. Med. 346 2002 896 903 (Pubitemid 34984638)
42. T.A. Sarafian, S. Kouyoumjian, D. Tashkin, and M.D. Roth Synergistic cytotoxicity of Delta(9)-tetrahydrocannabinol and butylated hydroxyanisole Toxicol. Lett. 133 2002 171 179 (Pubitemid 34761974)
43. T.A. Sarafian, L. Vartavarian, D.J. Kane, D.E. Bredesen, and M.A. Verity bcl-2 expression decreases methyl mercury-induced free-radical generation and cell killing in a neural cell line Toxicol. Lett. 74 1994 149 155 (Pubitemid 24292033)
44. M.S. Shive, and J.M. Anderson Biodegradation and biocompatibility of PLA and PLGA microspheres Adv. Drug Deliv. Rev. 28 1997 5 24 (Pubitemid 27497671)
45. C. Thomas, A. Rawat, S. Bai, and F. Ahsan Feasibility study of inhaled hepatitis B vaccine formulated with tetradecylmaltoside J. Pharm. Sci. 97 2008 1213 1223
46. R. Vanbever, J.D. Mintzes, J. Wang, J. Nice, D. Chen, R. Batycky, R. Langer, and D.A. Edwards Formulation and physical characterization of large porous particles for inhalation Pharm. Res. 16 1999 1735 1742 (Pubitemid 29530407)
47. T. Yang, A. Hussain, S. Bai, I.A. Khalil, H. Harashima, and F. Ahsan Positively charged polyethylenimines enhance nasal absorption of the negatively charged drug, low molecular weight heparin J. Control. Release 115 2006 289 297 (Pubitemid 44634847)